A recombinant live attenuated tetravalent vaccine for the prevention of dengue

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013 25;496:504–507.
   PubMed Web of Science ®Google Scholar
• Shepard DS, Undurraga EA, Halasa YA, et al. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16:935–941.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Harris E. Dengue. Lancet. 2015;385:453–465.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Dengue and severe dengue. Fact sheet No. 117. s.l. [ updated May]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/index.html
   Google Scholar
• Egger JR, Coleman PG. Age and clinical dengue illness. Emerg Infect Dis. 2007;13:924–925.
   PubMed Web of Science ®Google Scholar
• L’Azou M, Moureau A, Sarti E, et al. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med. 2016;374:1155–1166.
   PubMed Web of Science ®Google Scholar
• Teixeira MG, Siqueira JB Jr, Ferreira GL, et al. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7:e2520.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Renhorn KE, Tissera H, et al. DengueTools: innovative tools and strategies for the surveillance and control of dengue. Glob Health Action. 2012;5. DOI:10.3402/gha.v5i0.17273
   Web of Science ®Google Scholar
• Screaton G, Mongkolsapaya J, Yacoub S, et al. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745–759.
   PubMed Web of Science ®Google Scholar
• Guy B, Lang J, Saville M, et al. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387–404.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick BD, Durbin AP, Pierce KK, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis. 2015;212:702–710.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Huang CY, Kinney RM, et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29:7251—60.
   PubMed Web of Science ®Google Scholar
• George SL, Wong MA, Dube TJ, et al. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial. J Infect Dis. 2015;212:1032–1041.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Roehrig J, Barrett A, et al. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine. 2011;29:7276–7284.
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements DE, Bett AJ, et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011;29:7267–7275.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccines. 2006;2:60–67.
   PubMed Web of Science ®Google Scholar
• Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201:370–377.
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26:5712–5721.
   PubMed Web of Science ®Google Scholar
• Capeding RZ, Laot TM, Boaz M, et al. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials Vaccinol. 2015;4:19–23.
   Google Scholar
• Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29:3863–3872.
   PubMed Web of Science ®Google Scholar
• Poo J, Galan F, Forrat R, et al. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30:e9–e17.
   PubMed Web of Science ®Google Scholar
• Qiao M, Shaw D, Forrat R, et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85:724–731.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Galan-Herrera JF, Forrat R, et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother. 2014;10:2853–2863.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Thakur M, Boaz M, et al. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 2013;31:5047–5054.
   PubMed Web of Science ®Google Scholar
• Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32:1102–1109.
   PubMed Web of Science ®Google Scholar
• Tran NH, Luong CQ, Vu TQH, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3:1–7.
   Google Scholar
• Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30:5935–5941.
   PubMed Web of Science ®Google Scholar
• Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8:1259–1271.
   PubMed Web of Science ®Google Scholar
• Harenberg A, Begue S, Mamessier A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9:2317–2325.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Garbes P, Noriega F, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil. Am J Trop Med Hyg. 2013;89:1058–1065.
   PubMed Web of Science ®Google Scholar
• Dubey AP, Agarkhedkar S, Chhatwal J, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother. 2016;12:512–518.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559–1567.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195–1206.
   PubMed Web of Science ®Google Scholar
• Gailhardou S, Skipetrova A, Dayan GH, et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. Plos Negl Trop Dis. 2016;10:e0004821.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384:1358–1365.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Wartel Tram A, Frago C, et al. Long-term safety of the CYD-TDV dengue vaccine in Asia-Pacific dengue endemic countries. 5th Pan American Dengue Research Meeting, Panama City; 2016; Abstract # R86.
   Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372:113–123.
   PubMed Web of Science ®Google Scholar
• Torresi J, Heron LG, Qiao M, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomized study. Vaccine. 2015;33:5127–5134.
   PubMed Web of Science ®Google Scholar
• Hss AS, Koh MT, Tan KK, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: a randomized, placebo-controlled, phase III study. Vaccine. 2013;31:5814–5821.
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632–649.
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29:7229–7241.
   PubMed Web of Science ®Google Scholar
• Guy B, Briand O, Lang J, et al. Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33:7100–7111.
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Biological Standardization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). WHO Tech. Rep. Ser. No. 979, Annex 2 (replacement of Annex 1 of WHO Tech. Rep. Ser. No. 932). Geneva: World Health Organization; 2011.
   Google Scholar
• WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. ISBN 92 4 154500 3 (NLM Classification: WC 528); Geneva, World Health Organization; 1997.
   Google Scholar
• Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci USA. 2015;112(47):14688–14693.
   PubMed Web of Science ®Google Scholar
• Olivera-Botello G, Coudeville L, Fanouillere K, et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America. J Infect Dis. 2016;214(7):994–1000.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54:1615–1617.
   PubMed Web of Science ®Google Scholar
• Dengue vaccine: WHO position paper – July 2016. Weekly epidemiological record. 2016;30:349–364.
   Google Scholar
• Flasche S, Jit M, Rodríguez-Barraquer I, et al. The long term safety, public health impact, and cost effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med. 2016;13(11):e1002181.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-García JL, Guy B, et al. Answer to the review from Halstead and Russell “Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:4273–4274.
   PubMed Web of Science ®Google Scholar
• Arredondo-García JL, Hadinegoro SRS, Guy B, et al. Is discussion of dengue vaccination for the 2016 Olympics necessary? Lancet. 2016;388(10054):1880–1881.
   PubMed Web of Science ®Google Scholar
• Laoprasopwattana K, Libraty DH, Endy TP, et al. Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis. 2005;192:510–519.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Acosta LP, Tallo V, et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6:e1000171.
   PubMed Web of Science ®Google Scholar
• Murgue B. Severe dengue: questioning the paradigm. Microbes Infect. 2010;12:113–118.
   PubMed Web of Science ®Google Scholar
• Byers AM, Broder R, Haupfear KT, et al. Influence of FcγRIIa-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live attenuated tetravalent dengue vaccine. Open Forum Infect Dis. 2015;2:ofv172.
   PubMedGoogle Scholar
• Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10:712—22.
   PubMed Web of Science ®Google Scholar
• Harenberg A, de Montfort A, Jantet-Blaudez F, et al. Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials. Plos Negl Trop Dis. 2016;10:e0004830.
   PubMed Web of Science ®Google Scholar
• Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14:45–54.
   PubMed Web of Science ®Google Scholar
• Coudeville L, Baurin N, L’Azou M, et al. Potential impact of dengue vaccination: insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine. 2016;34(50):6426–6435.
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Rodríguez-Barraquer I, Dorigatti I, et al. Benefits and risks of the Sanofi Pasteur dengue vaccine: modeling optimal deployment. Science. 2016;353:1033–1036.
   PubMed Web of Science ®Google Scholar